Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly ...

The U.S. Food and Drug Administration said a comprehensive review “found no increased” risk related to suicide among users of ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Eli Lilly working Humana to distribute obesity medications through employer-focused programs via CenterWell Pharmacy.

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

US at a fraction of the cost of injectable versions – has rather stolen their thunder. Patients used to paying more than ...

People who stop taking weight-loss jabs such as Wegovy regain pounds much faster than those who halt exercising and dieting, ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts ...